Immunomedics, Inc. (NASDAQ:IMMU) Files An 8-K Regulation FD Disclosure
Item7.01. Regulation FD Disclosure.
On February 17, 2017, Immunomedics, Inc. issued a press release
titled Immunomedics Presents Updated Results with Sacituzumab
Govitecan (IMMU-132) in Heavily Pretreated Patients with
Metastatic Urothelial Cancer. The full text of the press release
is attached to this current report on Form8-K as Exhibit99.1 and
is incorporated by reference herein.
Also on February 17, 2017, at the Genitourinary Cancers Symposium
being held at Rosen Shingle Creek in Orlando, Florida, the
Company displayed a poster entitled Therapy for Chemo-Pretreated
Metastatic Urothelial Cancer (mUC) with the Antibody-Drug
Conjugate (ADC), Sacituzumab Govitecan (IMU-132). The full text
of the poster is attached to this current report on Form 8-K as
Exhibit 99.2, and is incorporated by reference herein.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
|
Exhibit No. |
Description of Exhibit |
|
| 99.1 |
Press Release of Immunomedics, Inc., dated February 17, 2017, titled Immunomedics Presents Updated Results with Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients with Metastatic Urothelial Cancer. |
|
| 99.2 |
Genitourinary Cancers Symposium Poster: Therapy for Chemo-Pretreated Metastatic Urothelial Cancer (mUC) with the Antibody-Drug Conjugate (ADC), Sacituzumab Govitecan (IMU-132). |
About Immunomedics, Inc. (NASDAQ:IMMU)
Immunomedics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing monoclonal antibody-based products for the targeted treatment of cancer, autoimmune disorders and other serious diseases. Its geographic segments include United States and Europe. Its technologies allow it to create humanized antibodies that can be used either alone in unlabeled or naked form, or conjugated with radioactive isotopes, chemotherapeutics, cytokines or toxins. It has a pipeline of eight clinical-stage product candidates. Its portfolio of investigational products includes antibody-drug conjugates (ADCs) that are designed to deliver a payload of a chemotherapeutic directly to the tumor, while the managing overall toxic effects that are found with conventional administration of these chemotherapy agents. Its ADCs are sacituzumab govitecan (IMMU-132) and labetuzumab govitecan (IMMU-130), which are in Phase II trials. Immunomedics, Inc. (NASDAQ:IMMU) Recent Trading Information
Immunomedics, Inc. (NASDAQ:IMMU) closed its last trading session up +0.23 at 5.34 with 5,696,541 shares trading hands.